Effect of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on telomerase activity in pancreatic cancer-derived cell lines

Pancreatology

Volumn 9, Issue 4, 2009, Pages 360-368

  Kumari, Alpana ^a   Srinivasan, Radhika ^a   Wig, Jai Dev ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

5 Azacytidine; C MYC; E2F1; HTERT; Methylation; Pancreatic cancer; SiRNA; Telomerase

Indexed keywords

AZACITIDINE; MESSENGER RNA; MYC PROTEIN; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER CELL CULTURE; CELL IMMORTALIZATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; E2F1 GENE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOGENE C MYC; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; TRANSCRIPTION REGULATION; TUMOR GENE;

EID: 65649090276     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000212094     Document Type: Article

References (32)

1. Horikawa I, Cable PL, Afshari C, Barrett JC: Cloning and characterization of the promoter region of human telomerase reverse tran-scriptase gene. Cancer Res 1999; 59:826- 830.
2. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G: Reversible activation of c-MYC in skin: induction of a complex neoplastic phe-notype by a single oncogenic lesion. Mol Cell 1999; 3:565-577.
3. Jain M, Arvanitis C, Chu K, Dewey W, Leon-hardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-104.
4. Horikawa I, Barrett JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24: 1167-1176.
5. Misiti S, Nanni S, Fontemaggi G, et al: Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000; 20:3764- 3771.
6. Oh S, Song YH, Yim J, Kim TK: Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000; 19: 1485-1490.
7. Crowe DL, Nguyen DC, Tsang KJ, Kyo S: E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 2001; 29: 2789-2794.
8. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, McDonald JM, Yung WKA, Manzano CG: Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 2005; 97:1589-1600.
9. Elliott KA, Rickords LF, Labrum JM: Trans-duction of E2F-1 TAT fusion proteins represses expression of hTERT in primary duc-tal breast carcinoma cell lines. Mol Cancer 2008; 7:28.
10. Felsher DW, Bishop JM: Reversible tumori-genesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207.
11. Ebihara Y, et al: Overexpression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression. Dis Esophagus 2004; 17: 150 -154.
12. Nomoto K, Maekawa M, Sugano K, Ushiama M, Fukayama N, Fujita S, Kakizoe T: Meth-ylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation of the p16 gene in colorectal cancer as analyzed by bisulfite PCR-SSCP. Jpn J Clin Oncol 2002; 32:3-8.
13. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC: DNA methyla-tion analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 1999; 59:6087-6090.
14. Dessain SK, Yu HY, Reddel RR, Beijersber-gen RL, Weinberg RA: Methylation of the human telomerase gene CpG island. Cancer Res 2000; 60:537-541.
15. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20:85-93.
16. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello M, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-9826.
18. Laemmli UK: Cleavage of the structural proteins during the assembly of head of bacteriophage T4. Nature 1970; 227:680-685.
19. Towbin H, Skachelin T, Gordon J: Electro-phoretic transfer of proteins from polyacryl-amide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
20. Holt SE, Aisner DL, Shay JW, Wright WE: Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 1997; 94:10687-10692.
21. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al: A phase II study of 5-aza-2′-deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 1998; 84: 87-89.
22. Kitagawa Y, Kyo S, Takakura M, Kanaya T, Kashida K, Namiki M, et al: Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res 2000; 6:2868-2875.
23. Gunes C, Lichtsteiner S, Vasserot AP, Eng-lert C: Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res 2000; 60: 2116-2121.
24. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, Henriksson M: Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 2001; 98: 3826-3831.
25. Wu KJ, Grandori C, Amacker M, Simon-Ver-mot N, Polack A, Lingner J, Dalla-Favera R: Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21:220-224.
26. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, De Pinho RA: Telomerase reverse transcriptase gene is a direct target of c-MYC but is not functionally equivalent in cellular transformation. Oncogene 1999;18: 1219-1226.
27. Wang J, Xie LY, Allan S, Beach D, Hannon GJ: Myc activates telomerase. Genes Dev 1998; 12:1769-1774.
28. Fujimoto K, Takahashi M: Telomerase activity in human leukemic cell lines is inhibited by antisense pentadeoxynucleotides targeted against c-myc mRNA. Biochem Biophys Res Commun 1997; 241: 775 -781.
29. Johnson DG: The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog 2000; 27: 151-157.
30. Alonso MM, Fueyo J, Yung WKA, Gomez-Manzano C: E2F1 and telomerase: alliance in the dark side. Cell Cycle 2006; 5: 930 -935.
31. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG: Increased E2F1 activity induces skin tumors in mice heterozygous and nul-lizygous for p53. Proc Natl Acad Sci USA 1998; 95: 8858-8863.
32. Oswald F, Lovec H, Moroy T, Lipp M: E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Onco-gene 1994; 9:2029-2036.